atorvastatin has been researched along with Thrombosis in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 6 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Abedini, A; Abri, H; Aghakouchakzadeh, M; Aliannejad, R; Amin, A; Ansarin, K; Baghizadeh, E; Bakhshandeh, H; Barco, S; Beigmohammadi, MT; Bikdeli, B; Dabbagh, A; Eslami, V; Farrokhpour, M; Goldhaber, SZ; Gupta, A; Hadavand, N; Hajighasemi, A; Hosseini, SH; Jamalkhani, S; Jimenez, D; Kakavand, H; Kashefizadeh, A; Khalili, H; Kirtane, AJ; Klok, FA; Krumholz, HM; Lip, GYH; Lookzadeh, S; Madhavan, MV; Maleki, M; Matin, S; Moghadam, KG; Mohammadi, K; Mohebbi, B; Monreal, M; Mousavian, SM; Najafi, A; Parhizgar, SE; Parikh, SA; Payandemehr, P; Piazza, G; Rafiee, F; Rahmani, H; Rashidi, F; Rezaeifar, P; Rezaian, S; Riahi, T; Sadeghian, S; Sadeghipour, P; Sethi, SS; Sezavar, SH; Shafaghi, S; Sharif-Kashani, B; Siegerink, B; Soleimanzadeh, M; Spatz, ES; Stone, GW; Tabrizi, S; Tahamtan, O; Talakoob, H; Talasaz, AH; Tassell, BWV; Tojari, T; Yadollahzadeh, M; Zoghi, E | 1 |
| Coxon, FP; Jalal, MM; Mutch, NJ; Whyte, CS | 1 |
| Hu, M; Peng, X; Pu, X; Shi, S; Yu, X | 1 |
| Cui, J; Grau, MS; Jaffer, FA; Jhajj, HS; Kessinger, CW; Libby, P; McCarthy, JR; Misra, S | 1 |
| Abedini, A; Amin, A; Bakhshandeh, H; Beigmohammadi, MT; Bikdeli, B; Dabbagh, A; Farrokhpour, M; Goldhaber, SZ; Gupta, A; Hadavand, N; Hajighasemi, A; Jamalkhani, S; Jimenez, D; Khalili, H; Kirtane, AJ; Krumholz, HM; Lip, GYH; Lookzadeh, S; Madhavan, MV; Maleki, M; Matin, S; Mohebbi, B; Monreal, M; Parhizgar, SE; Parikh, SA; Payandemehr, P; Piazza, G; Rashidi, F; Rezaeifar, P; Riahi, T; Sadeghian, S; Sadeghipour, P; Sezavar, H; Shahmirzaei, S; Sharif-Kashani, B; Tahamtan, O; Talasaz, AH; Yadollahzadeh, M | 1 |
| Bolek, T; Galajda, P; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J; Vádelová, Ľ | 1 |
| Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A | 1 |
| Carnevale, R; Pastori, D; Pignatelli, P; Violi, F | 1 |
| Ebensperger, R; Hidalgo, P; Massardo, T; Mezzano, D; Panes, O; Pereira, J; Pereira-Flores, K; Sáez, CG | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Gao, J; Gao, X; Pan, S; Zhao, Z | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F | 1 |
| Barderas, MG; Dardé, VM; De la Cuesta, F; Egido, J; Jiménez-Nácher, JJ; López-Bescós, L; Tarín, N; Tuñón, J; Vivanco, F | 1 |
| Coplan, N; Gintautas, J; Gupta, MP; Labana, SS; Polena, S; Shaikh, H; Soffer, D; Zazzali, K | 1 |
| Adamson, U; Antovic, A; Henriksson, P; Jörneskog, G; Lins, PE; Mobarrez, F; Santesson, P; Tehrani, S; Wallén, NH | 1 |
| Doi, M; Fukushima, H; Hamada, M; Matsui, H; Mizuno, T; Nishio, K; Shida, Y; Shima, M; Sugimoto, M; Yoshioka, A | 1 |
| Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P | 1 |
| Arbustini, E; Camera, M; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Negri, A; Rossi, F; Tremoli, E | 1 |
| Asakura, H; Ishino, C; Kanno, M; Matsuda, T; Minami, S; Morishita, E; Nakao, S; Uotani, C | 1 |
| Gaddam, V; Li, DY; Mehta, JL | 1 |
| Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, E; Martínez, M | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Alfon, J; Badimon, L; Pueyo Palazon, C; Royo, T | 1 |
| Ahotupa, M; Kantola, I; Nieminen, MS; Strandberg, T; Vanhanen, H; Vasankari, T; Viikari, J | 1 |
| Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P | 1 |
2 review(s) available for atorvastatin and Thrombosis
| Article | Year |
|---|---|
Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition.
Topics: Animals; Antioxidants; Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Reactive Oxygen Species; Thrombosis | 2014 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
11 trial(s) available for atorvastatin and Thrombosis
| Article | Year |
|---|---|
Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial.
Topics: Adult; Atorvastatin; COVID-19; Double-Blind Method; Female; Humans; Intensive Care Units; Male; Middle Aged; Thrombosis; Treatment Outcome | 2023 |
Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Topics: Anticoagulants; Atorvastatin; COVID-19; COVID-19 Drug Treatment; Critical Illness; Double-Blind Method; Enoxaparin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Thrombosis; Time Factors; Treatment Outcome; Venous Thromboembolism | 2020 |
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
Topics: Aged; Atorvastatin; Clopidogrel; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Thrombosis; Ticlopidine | 2014 |
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography | 2009 |
Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression; Gene Expression Profiling; Heat-Shock Proteins; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Statistics, Nonparametric; Tandem Mass Spectrometry; Thrombosis | 2009 |
Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thrombosis; Ticlopidine | 2008 |
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Platelets; C-Reactive Protein; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Dyslipidemias; Fibrin; Fibrinolytic Agents; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta3; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Pyrroles; Sweden; Thrombin; Thromboplastin; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins; Macrophages; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Antigens; Atorvastatin; Blood Glucose; Factor VII; Female; Fibrinogen; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Isoantigens; Male; Middle Aged; Pyrroles; Risk Factors; Thrombosis; Triglycerides | 2002 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis | 2002 |
13 other study(ies) available for atorvastatin and Thrombosis
| Article | Year |
|---|---|
Atorvastatin-mediated inhibition of prenylation of Rab27b and Rap1a in platelets attenuates their prothrombotic capacity and modulates clot structure.
Topics: Adenosine Diphosphate; Atorvastatin; Blood Platelets; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prenylation; rab GTP-Binding Proteins; rap1 GTP-Binding Proteins; Thrombosis | 2023 |
A synergistic strategy of dual-crosslinking and loading intelligent nanogels for enhancing anti-coagulation, pro-endothelialization and anti-calcification properties in bioprosthetic heart valves.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Atorvastatin; Bioprosthesis; Calcinosis; Glutaral; Heart Valve Prosthesis; Heart Valves; Heparin; Hydrogen Peroxide; Inflammation; Nanogels; Schiff Bases; Sulfonic Acids; Swine; Thrombosis | 2023 |
Atorvastatin Reduces
Topics: Animals; Arteriovenous Shunt, Surgical; Atorvastatin; Carotid Artery, Internal; Collagen; Female; Fibrin; Fibrosis; Hemorheology; Inflammation; Jugular Veins; Macrophages; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Nanoparticles; Random Allocation; RNA, Messenger; Thrombosis; Transcription, Genetic; Vascular Access Devices; Vascular Patency | 2020 |
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombosis | 2021 |
Atorvastatin reduces the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro.
Topics: Anticholesteremic Agents; Atorvastatin; Caveolin 1; Cell Adhesion; Cells, Cultured; Cocaine; Cocaine-Related Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; In Vitro Techniques; Nitric Oxide; Nitric Oxide Synthase Type III; Phenotype; Plasma; Pyrroles; Reactive Oxygen Species; Thrombosis; von Willebrand Factor | 2014 |
[Expression of cyclophilin A/CD147 in carotid atherosclerotic plaque and the intervention of atorvastatin].
Topics: Animals; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, Dietary; Cyclophilin A; Macrophages; Male; Plaque, Atherosclerotic; Rabbits; Random Allocation; Thrombosis; Triglycerides | 2016 |
Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
Topics: Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; P-Selectin; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Regional Blood Flow; Stress, Mechanical; Thrombin; Thromboplastin; Thrombosis; Time Factors; von Willebrand Factor | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid Stenosis; Clopidogrel; Colitis, Ulcerative; Female; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Lipoprotein(a); Magnetic Resonance Imaging; Middle Aged; Pyrroles; Risk Factors; Stroke; Thrombosis; Ticlopidine; Ultrasonography | 2011 |
Anti-thrombotic effects of atorvastatin--an effect unrelated to lipid lowering.
Topics: Animals; Aorta, Abdominal; Atorvastatin; Fibrinolytic Agents; Heptanoic Acids; Lipids; Male; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Thrombosis | 2002 |
Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
Topics: Adenosine Diphosphate; Adult; Aged; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Risk Factors; Thrombin; Thrombosis | 2005 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Topics: Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Platelet Adhesiveness; Platelet Aggregation; Pyrroles; Rabbits; Simvastatin; Thrombosis | 1999 |
Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Oxidation-Reduction; Pyrroles; Sympatholytics; Thrombosis; Triglycerides | 2001 |